Analogs of growth hormone-releasing factor (1-29) amide containing the reduced peptide bond isostere in the N-terminal region
- 1 July 1990
- journal article
- research article
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 33 (7) , 1954-1958
- https://doi.org/10.1021/jm00169a022
Abstract
Previous peptide structure-activity investigations employing the .psi.[CH2NH] peptide bond isostere have produced antagonists when inserted into various sequences. These include bombesin, in which the incorporation of Leu13.psi.[CH2NH]Leu14 produced a potent antagonist, and tetragastrin, with which Boc-Trp-Leu.psi.[CH2NH]Asp-Phe-NH2 is an antagonist. In this study, we chose to investigate the effect of this isostere on growth hormone-releasing factor (1-29) amide. Analogues were prepared by solid-phase synthesis and the isosteres incorporated by racemization-free reductive alkylation with a preformed protected amino acid aldehyde in the presence of NaBH3CN. The aldehydes were prepared by the reduction of the protected N,O-dimethyl hydroxamates with LiAlH4 at 0.degree. C. The purified analogues were assayed in a 4-day primary culture of male rat anterior pituitary cells for growth hormone (GH) release. Potential antagonists were retested in the presence of GRF(1-29)NH2. The following results were obtained: At position 5-6, a very weak agonist was produced with .mchlt. 0.01% activity. Incorporation of the isostere in positions 1-2, 2-3, and 6-7 gave weak agonists with .apprx. 0.1% activity. Agonists with 0.39% and 1.6% activity were produced by incorporation at 10-11 and 3-4, respectively. The analogue [Ser9.psi.[CH2NH]Try10]GRF(1-29)NH2 was found to be an antagonist in the 10 .mu.M range vs 1 nM GRF and had no agonist activity at doses as high as 0.1 mM.This publication has 15 references indexed in Scilit:
- Differential effects of N-terminal modifications on the biological potencies of growth hormone releasing factor analogs with varying chain lengthsJournal of Medicinal Chemistry, 1986
- Solution structure of human growth hormone releasing factorJournal of Molecular Biology, 1986
- Rapid enzymatic degradation of growth hormone-releasing hormone by plasma in vitro and in vivo to a biologically inactive product cleaved at the NH2 terminus.Journal of Clinical Investigation, 1986
- Amphiphilic growth hormone releasing factor (GRF) analogs: Peptide design and biological activity in vivoBiochemical and Biophysical Research Communications, 1986
- Synthesis and biological activities of some pseudo-peptide analogs of tetragastrin: the importance of the peptide backboneJournal of Medicinal Chemistry, 1985
- Structural Requirements for the Activation of Rat Anterior Pituitary Adenylate Cyclase by Growth Hormone–Releasing Factor (GRF): Discovery of (N–Ac–Tyr1,d–Arg2)–GRF(l–29)–NH2as a GRF Antagonist on Membranes*Endocrinology, 1985
- An Extremely Sensitivein VitroModel for Elucidating Structure-Activity Relationships of Growth Hormone-Releasing Factor Analogs*Endocrinology, 1985
- Prolactin secretion by cultured anterior pituitary cells: influence of culture conditions and endocrine status of the pituitary donorMolecular and Cellular Endocrinology, 1984
- Super-active analogs of growth hormone-releasing factor (1–29)-amideBiochemical and Biophysical Research Communications, 1984
- Growth Hormone-Releasing Factor from a Human Pancreatic Tumor That Caused AcromegalyScience, 1982